Single-Lead AI-Enabled ECG Serves as a Powerful Noninvasive Screening Tool: Study Confirms

Written By :  Aashi verma
Published On 2026-03-24 15:45 GMT   |   Update On 2026-03-24 15:46 GMT

A recent study confirms that a single-lead artificial intelligence (AI)-enabled electrocardiogram (ECG) serves as a powerful non-invasive screening tool for hyperkalemia, achieving an internal area under the receiver operating characteristic curve (AUROC) of 0.936 and a negative predictive value (NPV) exceeding 99.3% in external cohorts.

Hyperkalemia is a frequently fatal electrolyte disorder particularly prevalent in patients with chronic kidney disease (CKD) and heart failure (HF), yet current detection methods remain hindered by the need for invasive venous blood sampling and clinical facility access. Although previous deep learning models using 12-lead ECG data have shown promise, a significant clinical gap exists for scalable home monitoring, leading Gongzheng Tang and colleagues from the Peking University Health Science Center to develop Pocket-K with the aim of providing a reliable, single-lead AI screening solution.

Therefore, the multicenter observational study utilized a dataset of 62,290 ECG–potassium pairs from 34,439 unique patients across two independent Chinese tertiary health systems between 2016 and 2024 to fine-tune a pretrained foundation model for detecting serum potassium levels greater than 5.5 mmol/L. By extracting Lead I data and excluding samples with laboratory-confirmed hemolysis or those lacking a paired measurement within a strict one-hour window, the researchers established primary and secondary endpoints focused on diagnostic discrimination across internal, temporal, and external validation settings.

Key Clinical Findings of Study Include:

  • High Internal Accuracy: The study found that Pocket-K achieved a robust AUROC of 0.936 with a sensitivity of 83.33% during initial testing.

  • Robust External Reliability: Even when tested in a geographically independent health system using different hardware platforms, the model maintained a commendable AUROC of 0.808, affirming the study's generalizability.

  • Superior Severe Detection: For clinically urgent moderate-to-severe elevations of 6.0 mmol/L or higher, the AUROC increased to 0.861 in the external validation set, as the study noted.

  • Reliable Rule-Out Capacity: The system demonstrated an NPV of 99.91% for moderate-to-severe events, suggesting the study's potential for identifying low-risk states.

  • Rapid Clinical Inference: A handheld prototype from the study successfully executed near-real-time risk estimation via a smartphone application, returning risk probabilities for normokalemic and severe examples within seconds.

The results suggest that this foundation-model-based approach provides stable discrimination for hyperkalemia across heterogeneous populations, maintaining a high NPV above 99.3% while accurately tracking individual longitudinal potassium trajectories.

These findings indicate that clinicians can utilize single-lead AI systems as non-invasive rule-out tools to enhance the frequency of potassium surveillance for patients at high cardiorenal risk.

Although the study is limited by its retrospective design and geographic concentration in China, it underscores a clear need for future research using native consumer recordings to assess the impact of AI-guided screening on clinical decision-making.

Reference

Tang G, Zhao Q, Nie G, et al. Artificial intelligence-enabled single-lead ECG for non-invasive hyperkalemia detection: development, multicenter validation, and proof-of-concept deployment. 2026.



Tags:    
Article Source : arXiv

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News